On November 20, Revolution Medicines, Inc. posted an Intraday Rise of 4.21% in Regular Trading, trading at $167.56/share, with turnover of $163.0 million.
The move was closely tied to updated Phase 1/2 data for Rasonque plus chemotherapy in previously untreated metastatic pancreatic cancer, where the company reported a 60.7% objective response rate and durable tumor responses, with safety consistent with prior observations.
The update also reinforced the rationale for the ongoing Phase 3 RASolute 303 study. As added context, the company had just received European Commission approval for Rasonque as a monotherapy for metastatic pancreatic adenocarcinoma across EU and EEA markets, based on a Phase 3 trial that met all primary and key secondary endpoints, supporting investor expectations for broader commercialization and indication expansion.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)